CORE EVIDENCE : Impact Factor & More
eISSN: 1555-175XpISSN: 1555-1741
Share this on:
Aims and Scope of CORE EVIDENCE
Core Evidence is a peer-reviewed healthcare journal covering research on drug development. The journal was established in 2005 and is published by Dove Medical Press.
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
CORE EVIDENCE Journal Specifications
Indexed in the following public directories
Web of Science
| Overview | |
| Publisher | DOVE MEDICAL PRESS LTD |
| Language | English |
| Frequency | Continuous publication |
| General Details |
View less
Planning to publish in CORE EVIDENCE ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in CORE EVIDENCE
Vedolizumab in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Safety, Efficacy, and Place of Therapy.
- 1 Apr 2020
- Core Evidence
Core Evidence
- 20 Jan 2020
- Core evidence
Pertuzumab in the treatment of HER2-positive breast cancer: an evidence-based review of its safety, efficacy, and place in therapy.
- 1 Oct 2019
- Core Evidence
Tedizolid phosphate for the treatment of acute bacterial skin and skin-structure infections: an evidence-based review of its place in therapy
- 5 Jul 2019
- Core Evidence
Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review [Erratum]
- 27 Feb 2019
- Core Evidence
Eslicarbazepine acetate in the treatment of adults with partial-onset epilepsy: an evidence-based review of efficacy, safety and place in therapy.
- 1 Mar 2018
- Core Evidence
Vedolizumab in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Safety, Efficacy, and Place of Therapy.
- 1 Apr 2020
- Core Evidence
Core Evidence
- 20 Jan 2020
- Core evidence
Pertuzumab in the treatment of HER2-positive breast cancer: an evidence-based review of its safety, efficacy, and place in therapy.
- 1 Oct 2019
- Core Evidence
Tedizolid phosphate for the treatment of acute bacterial skin and skin-structure infections: an evidence-based review of its place in therapy
- 5 Jul 2019
- Core Evidence
Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review [Erratum]
- 27 Feb 2019
- Core Evidence
Eslicarbazepine acetate in the treatment of adults with partial-onset epilepsy: an evidence-based review of efficacy, safety and place in therapy.
- 1 Mar 2018
- Core Evidence
FAQs on CORE EVIDENCE
How long has CORE EVIDENCE been actively publishing? 
What is the publishing frequency of CORE EVIDENCE?
How many articles did CORE EVIDENCE publish last year?
What is the eISSN & pISSN for CORE EVIDENCE?
Who is the publisher of CORE EVIDENCE?
